Jacky Luiten

Patterns of treatment and outcome of ductal carcinoma in situ in the Netherlands | 111 7 22. Veronesi U, Cascinelli N, Mariani L et al: Twenty ‐ year follow ‐ up of a randomized study comparing breast ‐ conserving surgery with radical mastectomy for early breast cancer. N Engl J Med 2002; 347(16):1227 ‐ 1232. 23. Del Turco MR, Mantellini P, Ciatto S et al: Full ‐ field digital versus screen ‐ film mammography: comparative accuracy in concurrent screening cohorts. AJR Am J Roentgenol 2007;189(4):860 ‐ 866. 24. Karssemeijer N, Bluekens AM, Beijerinck D et al: Breast cancer screening results 5 years after introduction of digital mammography in a population ‐ based screening program. Radiology 2009; 253(2):353 ‐ 358. 25. Morrow M, Van Zee KJ, Solin LJ et al: Society of Surgical Oncology ‐ American Society for Radiation Oncology ‐ American Society of Clinical Oncology Consensus Guideline on Margins for Breast ‐ Conserving Surgery With Whole ‐ Breast Irradiation in Ductal Carcinoma in Situ. Pract Radiat Oncol 2016;6(5):287 ‐ 295. 26. Cuzick J, Sestak I, Pinder SE, Ellis IO, Forsyth S, Bundred NJ, Forbes JF, Bishop H, Fentiman IS, George WD. Effect of tamoxifen and radiotherapy in women with locally excised ductal carcinoma in situ: long ‐ term results from the UK/ANZ DCIS trial. Lancet Oncol 2011;12(1):21 ‐ 29. 27. Wapnir IL, Dignam JJ, Fisher B et al: Long ‐ term outcomes of invasive ipsilateral breast tumor recurrences after lumpectomy in NSABP B ‐ 17 and B ‐ 24 randomized clinical trials for DCIS. J Natl Cancer Inst 2011;103(6):478 ‐ 488. 28. Correa C, McGale P, Taylor C et al: Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast. J Natl Cancer Inst Monogr 2010;2010(41):162 ‐ 177. 29. Hamdi M, Wolfli J, Van Landuyt K: Partial mastectomy reconstruction. Clin Plast Surg 2007; 34(1):51 ‐ 62; abstract vi. 30. Kaufman EL, Jacobson JS, Hershman DL et al: Effect of breast cancer radiotherapy and cigarette smoking on risk of second primary lung cancer. J Clin Oncol 2008;26(3):392 ‐ 398. 31. Taylor C, Correa C, Duane FK et al: Estimating the Risks of Breast Cancer Radiotherapy: Evidence From Modern Radiation Doses to the Lungs and Heart and From Previous Randomized Trials. J Clin Oncol 2017;35(15):1641 ‐ 1649. 32. Taylor CW, Wang Z, Macaulay E et al: Exposure of the Heart in Breast Cancer Radiation Therapy: A Systematic Review of Heart Doses Published During 2003 to 2013. Int J Radiat Oncol Biol Phys 2015;93(4):845 ‐ 853. 33. Smyth LM, Knight KA, Aarons YK et al: The cardiac dose ‐ sparing benefits of deep inspiration breath ‐ hold in left breast irradiation: a systematic review. J Med Radiat Sci 2015;62(1):66 ‐ 73. 34. Silverstein MJ: An argument against routine use of radiotherapy for ductal carcinoma in situ. Oncology (Williston Park) 2003;17(11):1511 ‐ 1533; discussion 1533 ‐ 1514, 1539, 1542 passim. 35. Sagara Y, Freedman RA, Vaz ‐ Luis I et al: Patient Prognostic Score and Associations With Survival Improvement Offered by Radiotherapy After Breast ‐ Conserving Surgery for Ductal Carcinoma In Situ: A Population ‐ Based Longitudinal Cohort Study. J Clin Oncol 2016;34(11):1190 ‐ 1196. 36. van Maaren MC, Lagendijk M, Tilanus ‐ Linthorst MMA et al: Breast cancer ‐ related deaths according to grade in ductal carcinoma in situ: A Dutch population ‐ based study on patients diagnosed between 1999 and 2012. Eur J Cancer 2018;101:134 ‐ 142. 37. Francis AM, Haugen CE, Grimes LM et al: Is Sentinel Lymph Node Dissection Warranted for Patients with a Diagnosis of Ductal Carcinoma In Situ? Ann Surg Oncol 2015;22(13):4270 ‐ 4279. 38. Holm ‐ Rasmussen EV, Jensen MB, Balslev E et al: Risk factors of sentinel and non ‐ sentinel lymph node metastases in patients with ductal carcinoma in situ of the breast: A nationwide study. Breast (Edinburgh, Scotland) 2018;42:128 ‐ 132. 39. van Roozendaal LM, Goorts B, Klinkert M et al: Sentinel lymph node biopsy can be omitted in DCIS patients treated with breast conserving therapy. Breast Cancer Res Treat 2016;156(3):517 ‐ 525. 40. Elshof LE, Tryfonidis K, Slaets L et al: Feasibility of a prospective, randomised, open ‐ label, international multicentre, phase III, non ‐ inferiority trial to assess the safety of active surveillance for low risk ductal carcinoma in situ ‐ The LORD study. Eur J Cancer 2015;51(12):1497 ‐ 1510. 41. Francis A, Thomas J, Fallowfield L et al: Addressing overtreatment of screen ‐ detected DCIS; the LORIS trial. Eur J Cancer 2015;51(16):2296 ‐ 2303. 42. Van de Vijver MJ, Peterse H: The diagnosis and management of pre ‐ invasive breast disease: pathological diagnosis ‐‐ problems with existing classifications. Breast Cancer Res 2003;5(5):269.